Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.34 -4.3%	$1.34	$0.86 ▼ $3.78	$293.10M	0.31	3.32 million shs	2.45 million shs
AURA Aura Biosciences	$6.42 -3.7%	$5.76	$4.35 ▼ $12.38	$322.73M	0.42	209,933 shs	152,620 shs
CMPX Compass Therapeutics	$2.41	$2.00	$0.77 ▼ $4.08	$333.26M	1.41	952,012 shs	746,462 shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-4.29%	-5.63%	+40.64%	-30.93%	-47.86%
AURA Aura Biosciences	-3.75%	-1.23%	+31.02%	-12.65%	-11.33%
CMPX Compass Therapeutics	0.00%	-3.60%	+20.50%	-2.03%	+100.83%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.8425 of 5 stars	4.5	3.0	0.0	0.0	2.8	3.3	0.6
AURA Aura Biosciences	2.5195 of 5 stars	3.6	1.0	0.0	0.0	3.3	3.3	0.0
CMPX Compass Therapeutics	3.5675 of 5 stars	4.6	1.0	0.0	0.0	2.7	5.0	0.0
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	530.18% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	242.68% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	444.61% Upside
NTGN Neon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NTGN, AURA, CMPX, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	13,322.71	N/A	N/A	$3.04 per share	0.44
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$4.58 per share	N/A
CMPX Compass Therapeutics	$850K	392.07	N/A	N/A	$1.17 per share	2.06
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.23	N/A	N/A	N/A	N/A	-52.13%	-41.29%	8/6/2025 (Estimated)
AURA Aura Biosciences	-$76.41M	-$1.90	N/A	N/A	N/A	N/A	-41.57%	-36.43%	8/8/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A

Latest NTGN, AURA, CMPX, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
AURA Aura Biosciences	N/A	12.47	12.47
CMPX Compass Therapeutics	N/A	31.84	31.84
NTGN Neon Therapeutics	0.43	1.58	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
AURA Aura Biosciences	96.75%
CMPX Compass Therapeutics	68.43%
NTGN Neon Therapeutics	54.71%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
AURA Aura Biosciences	5.40%
CMPX Compass Therapeutics	29.80%
NTGN Neon Therapeutics	38.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	158.72 million	Optionable
AURA Aura Biosciences	50	50.27 million	47.25 million	Not Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable

NTGN, AURA, CMPX, and ALLO Headlines

Recent News About These Companies

Neon Gold Records, Avenue A unite to launch Futures Music Group

October 24, 2024 | musicbusinessworldwide.com

BioNTech grows in cell therapies, buying Kite's TCR platform

September 1, 2024 | pharmaphorum.com

Neon Trap Defense

April 14, 2024 | kotaku.com

BCYC Bicycle Therapeutics plc

April 9, 2024 | seekingalpha.com

neon oscillator

March 20, 2024 | hackaday.com

NTGN_old Historical Data

February 20, 2024 | investing.com

2000 Plymouth Neon

January 13, 2024 | cars.com

NBCO Neon Bloom, Inc.

December 22, 2023 | seekingalpha.com

Kansas City Ferris wheel could be out-dazzled by what will soon lie below: Neon Alley

November 13, 2023 | kansascity.com

Starfield Neon shops and locations – every vendor in Neon

November 4, 2023 | videogamer.com

A Nixie Clock With Neon Bulb Logic

October 5, 2023 | hackaday.com

Starfield | Where To Get Neon (Ne)

September 29, 2023 | hardcoregamer.com

Starfield Neon City guide – everything you need to know

September 14, 2023 | videogamer.com

Starfield: All Shops in Neon City

September 10, 2023 | twinfinite.net

Shadows in Neon

September 9, 2023 | ign.com

Starfield Neon city guide

August 19, 2023 | pcgamesn.com

Apex Legends Neon Network Collection Event

August 4, 2023 | ign.com

Fab Five: Neon fashion finds to brighten up your summer wardrobe

August 1, 2023 | vancouversun.com

Neon White physical edition for PS5, Switch launches September 15

July 21, 2023 | gematsu.com

Fast-paced platformer 'Neon White' is coming to Xbox

June 22, 2023 | engadget.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTGN, AURA, CMPX, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.34 -0.06 (-4.29%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.34 -0.01 (-0.37%)

As of 06/13/2025 07:07 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Aura Biosciences NASDAQ:AURA

$6.42 -0.25 (-3.75%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.40 -0.02 (-0.31%)

As of 06/13/2025 06:33 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Compass Therapeutics NASDAQ:CMPX

$2.41 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.00 (+0.21%)

As of 06/13/2025 07:23 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Neon Therapeutics NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time